- Home
- KTCC vs APLT Comparison
KTCC vs APLT Comparison
Compare KTCC & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTCC
- APLT
- Stock Information
- Founded
- KTCC 1969
- APLT 2016
- Country
- KTCC United States
- APLT United States
- Employees
- KTCC N/A
- APLT N/A
- Industry
- KTCC Electrical Products
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- KTCC Technology
- APLT Health Care
- Exchange
- KTCC Nasdaq
- APLT Nasdaq
- Market Cap
- KTCC 34.0M
- APLT 37.5M
- IPO Year
- KTCC N/A
- APLT 2019
- Fundamental
- Price
- KTCC $2.39
- APLT $0.33
- Analyst Decision
- KTCC
- APLT Buy
- Analyst Count
- KTCC 0
- APLT 7
- Target Price
- KTCC N/A
- APLT $6.10
- AVG Volume (30 Days)
- KTCC 25.2K
- APLT 2.3M
- Earning Date
- KTCC 05-06-2025
- APLT 04-14-2025
- Dividend Yield
- KTCC N/A
- APLT N/A
- EPS Growth
- KTCC N/A
- APLT N/A
- EPS
- KTCC N/A
- APLT N/A
- Revenue
- KTCC $514,394,000.00
- APLT $455,000.00
- Revenue This Year
- KTCC N/A
- APLT $3,031.87
- Revenue Next Year
- KTCC N/A
- APLT $312.01
- P/E Ratio
- KTCC N/A
- APLT N/A
- Revenue Growth
- KTCC N/A
- APLT N/A
- 52 Week Low
- KTCC $2.21
- APLT $0.30
- 52 Week High
- KTCC $6.14
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- KTCC 39.50
- APLT 36.05
- Support Level
- KTCC $2.25
- APLT $0.30
- Resistance Level
- KTCC $2.40
- APLT $0.38
- Average True Range (ATR)
- KTCC 0.13
- APLT 0.05
- MACD
- KTCC 0.01
- APLT -0.00
- Stochastic Oscillator
- KTCC 36.73
- APLT 17.19
About KTCC Key Tronic Corporation
Key Tronic Corp is an electronic manufacturing service provider. The company provides electronic manufacturing services to original equipment manufacturers in the United States and globally. Its primary services include integrated electronic and mechanical engineering, precision plastic molding, sheet metal fabrication, printed circuit board (PCB) and complete product assembly, component selection, sourcing and procurement, logistics, and new product testing and production. The firm derives a majority of its revenue from the United States.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.